Authors
Bijaya Gaire, Poulikos I Poulikakos
Published in
Cancer research. Volume 86. Issue 20. Pages 5017-5019. Oct 15, 2026.
Abstract
The RAS/MAPK pathway is among the most frequently dysregulated in human cancer, predominantly driven by activating mutations across RAS and BRAF in a broad spectrum of tumor types. The recent clinical validation of direct inhibitors of RAS, long considered undruggable, has reenergized the field and renewed focus on targeting the full RAS/MAPK axis. MEK, a central node in MAPK signaling, remains an attractive mutation-agnostic target, yet the efficacy of first-generation MEK inhibitors has been limited by pathway reactivation in tumors and by on-target, off-tissue toxicity. In this issue of Cancer Research, Kolitz and colleagues describe atebimetinib, a novel MEK inhibitor that also prevents feedback-induced MEK phosphorylation by RAF. The uniquely short plasma half-life of atebimetinib enables deep cyclic inhibition (DCI): transient but profound MEK/ERK output suppression with full recovery between doses. At each drug's tolerability limit, atebimetinib outperformed the MEK inhibitor binimetinib across multiple RAS- and BRAF-mutant tumor models. Whether DCI or suppression of MEK phosphorylation is the primary driver of the improved therapeutic window and how atebimetinib compares with the clinical standard and other MEK-targeting agents remain important open questions, but the work makes a compelling case that novel pharmacology can unlock therapeutic spaces at targets long considered exhausted. See related article by Kolitz et al., p. 5223.
PMID:
42876249
Bibliographic data and abstract were imported from PubMed on 15 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 11
- Comments 0